NEKTAR THERAPEUTICS — Director's Dealing 2021

Sep 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2021-09-22

Reporting Person: Ajer Jeffrey Robert (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-22	Common Stock	A	10200	$0.00	Acquired	36175	Direct
2021-09-22	Common Stock	S	3665	$17.78	Disposed	32510	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-22	Stock Option	$17.78	A	20400	Acquired	2029-09-21	Common Stock (20400)	Direct

Footnotes

F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2: This RSU award vests in full, one year following September 22, 2021.

F3: Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a "sell to cover" transaction.

F4: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021.